DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.

What the trial testedas reported · 720 people · 2022

Not counted

−6.50mmoL/moL−7.96 to −5.04

As reported

difference −6.50 mmoL/moL, 95% CI −7.96 to −5.04

Range includes no effect

1.5×0.7× to 3×

Bigger than 7 in 10 on the map

As reported

IRR 1.46, 95% CI 0.71–3.02

the abstract, start to end

… (estimated treatment difference [ETD] -6.50 mmoL/moL; 95% confidence …

… (estimated rate ratio 1.46; 95% CI 0.71, 3.02; P = .3008, …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−6.50−7.96 to −5.04

Hypoglycaemia

IRR 1.460.71–3.02

GLP-1 receptor agonistsInsulinGlycemic controlHypoglycaemia

1 / 3

2022

2023

2024

2025

2026

this paperpooled ittrialcites it